Johnson & Johnson Statement on West Virginia Opioid Settlement Agreement

NEW BRUNSWICK, N.J., April 18, 2022 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today announced a settlement agreement with the State of West Virginia and its participating subdivisions resolving their opioid-related claims against the Company. With this agreement, the Company is removed from the trial ongoing in Kanawha County, West Virginia.The $99 million settlement will directly support local community efforts to seek meaningful progress in addressing the opioid crisis in West Virginia. This settlement is not an admission of liability or wrongdoing and marks continued progress in resolving opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. The Company will continue to defend against any litigation that the final agreement does not resolve.The Company’s actions relating to the marketing and promotion of important prescription opioid medications were appropriate and responsible. DURAGESIC®, NUCYNTA® and NUCYNTA® ER accounted for less than one percent of total opioid prescriptions in West Virginia and the U.S. since launch. The Company no longer sells prescription opioid medications in the United States as part of its ongoing efforts to focus on transformational innovation and serving unmet patient needs. For more information, visit www.FactsAboutOurPrescriptionOpioids.com.Cautions Concerning Forward-Looking StatementsThis statement contains “f...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news